A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Pre-diabetes

In brief

The purpose of this research study is to examine if a combination of a cholesterol lowering-drug, simvastatin, with a sugar-lowering drug called rosiglitazone is more effective in improving vascular inflammation (irritation of the vessels that transport your blood) and other cardiovascular risk factors than the taking of simvastatin alone.

Key facts

Study ID

NCT00831129

Run by

University of Chicago

People needed

53

Starts

2006-09-01

Expected to finish

2011-04-01

Last updated by the study team

2017-02-10

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 21-75 years
• Metabolic syndrome (3 of the 5 components)
• Elevated waist circumference >40inches in men, >35inches in women
• Elevated triglycerides >150mg/dL
• Reduced HDL <40mg/dL in men, <50mg/dL in women
• Elevated blood pressure >130mmHg systolic, >85mmHg diastolic
• Elevated fasting glucose >100mg/dL

You may not qualify if…

• Diabetes mellitus
• Stage 3 hypertension >180mmHg systolic, >110mmHg diastolic office blood pressure
• History of non-diabetic kidney disease
• Myocardial infarction of unstable angina within the past 6 months
• History of liver disease
• History of malignancy
• History of drug or alcohol abuse
• Treatment with corticosteroids
• Pregnancy or lactating women of women of child bearing potential who are not willing to use reliable contraception method during the study

Where it is running

• University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.